| 不同诱导化疗方案联合放疗治疗鼻咽癌疗效分析 |
| |
| 引用本文： | 尹珍珍,王优优,张希梅,王凤明,赵路军,王平,王佩国,袁智勇. 不同诱导化疗方案联合放疗治疗鼻咽癌疗效分析[J]. 中国肿瘤临床, 2018, 45(4): 179-184. DOI: 10.3969/j.issn.1000-8179.2018.04.235 |
| |
| 作者姓名： | 尹珍珍 王优优 张希梅 王凤明 赵路军 王平 王佩国 袁智勇 |
| |
| 作者单位： | 天津医科大学肿瘤医院放射治疗科，国家肿瘤临床医学研究中心，天津市肿瘤防治重点实验室，天津市恶性肿瘤临床医学研究中 心（天津市300060） |
| |
| 摘 要： | 目的 分析诱导化疗后行调强放疗的鼻咽癌患者，对比不同诱导化疗方案的治疗疗效。 方法 回顾性分析2012年1月至2014年6月天津医科大学肿瘤医院初治170例Ⅱ~Ⅳb期鼻咽癌患者临床资料，其中男性126例，女性44例；Ⅱ期27例，Ⅲ期105例，Ⅳa~b期38例。 结果 全组中位随访时间34个月。3年总生存率、局部区域控制率、无病生存率和无远处转移生存率分别为82.8%、91.5%、76.7%和69.1%。多因素分析发现，含紫杉醇+顺铂的诱导化疗方案较顺铂+5-氟尿嘧啶疾病进展（HR:1.820，95%CI:1.013~3.271，P=0.045）及远处转移风险（HR:2.240，95%CI:1.017~4.090，P=0.045）显著降低。 结论 含紫杉醇+顺铂的诱导化疗方案较顺铂+5-氟尿嘧啶方案显著延长鼻咽癌患者无病生存率和无远处转移生存率。
|
| 关 键 词： | 鼻咽癌 诱导化疗 调强放疗 疗效 |
| 收稿时间： | 2017-11-16 |
Treatment outcomes of different induction chemotherapy regimens combined with intensity-modulated radiotherapy in nasopharyngeal carcinoma |
| |
| Affiliation: | Departments of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin 300060, China |
| |
| Abstract: | Objective The role of induction chemotherapy (IC) and preferred regimens is not very clear in non-endemic nasopharyngeal carcinoma (NPC) in northern China. Methods A total of 170 pathologically proven locoregional advanced NPCs between January 2012 and December 2014 were included in this analysis. One hundred and twenty-six were men and 44 patients were women. According to the American Joint Committee on Cancer (AJCC) 7th stage system, 48 patients were T1-2 and 77 patients were T3-4; 48 patients were N0-1 and 122 patients were N2-3; 27 patients were stage Ⅱ, 105 patients were stage Ⅲ, and 38 patients were stage IVa-b. Results The median follow-up time was 34 months. The 3-year overall survival (OS), locoregional failure-free survival (LRFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS) were 82.8%, 91.5%, 76.7%, and 69.1%, respectively. Multivariate analyses showed that IC with TPF (docetaxel, carboplatin, and fluorouracil) or TP (docetaxel and cisplatin) presented superior DFS and DMFS compared with PF (cisplatin+5-FU) [DFS-hazard ratio (HR): 1.820, 95% confidence interval (CI): 1.013-3.271, P=0.045; DMFS-HR: 2.240, 95% CI: 1.017-4.090, P=0.045]. Conclusions The IC regimens appeared to affect patients' outcomes, and TP-containing IC regimens conferred better DFS and DMFS than PF regimens. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
